You are here

Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44CA281563-01
Agency Tracking Number: R44CA281563
Amount: $399,586.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA22-176
Timeline
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-05-01
Award End Date (Contract End Date): 2024-04-30
Small Business Information
903 18TH ST
Santa Monica, CA 90403-3209
United States
DUNS: 117955789
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 FATEMEHSADAT MAJEDI
 (424) 542-1771
 majedi.negin@gmail.com
Business Contact
 FATEMEH SADAT MAJEDI
Phone: (424) 542-1771
Email: negin@symphonybiosciences.com
Research Institution
N/A
Abstract

Project Summary
Deaths from solid tumors vastly outnumber deaths from hematopoietic cancers. Yet progress in
immunotherapies for solid tumors is well behind those for lymphoma. CAR-T cell therapies and
engineered T cells have become revolutionary approaches for hematopoietic cancers, but their
potential for solid tumors is yet to be realized. Significant challenges hinder the potential of
immune therapies in solid tumors, including insufficient activation and eventual exhaustion of
effector T cells; and suppression of T cell effector responses in the tumor microenvironment. In
this proposal we consider these hurdles and offer a biomaterial solution that overcomes them.
This proposal is significant in facilitating endogenous T cells to fight solid tumors. Surgery is a
major treatment modality for both invasive and in situ tumors, but at this time, there are no specific
immunotherapies initiated at the time of surgery; they all start days to weeks later. Our proposal
is significant for offering a way to start treatments early, right at the time of initial surgery. Here
our synthetic scaffold, SymphNode can be injected at the time of biopsy or surgery not to only
recruit and active tumor-experienced local immune cells but also to suppress the inhibitory cells
created by tumor cells. Our long-term goal is to develop this bioengineered, locally injected,
“synthetic lymph node” into a therapy for human tumors.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government